Search | Clinical Trials Finder

Conditions: Ventricular Arrhythmias
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Ageing
Interventions: Blood Flow Restriction Training Exercise, Health Education; Behavioral
Lead sponsor: Baylor University; Other
Eligibility: 60 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Presbyopia
Interventions: 0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution, Placebo; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 47 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Glendale, California • Newport Beach, California • Morrow, Georgia + 9 more

Conditions: Thyroid Eye Disease (TED), Graves Ophthalmopathy, Thyroid Associated Ophthalmopathies
Interventions: Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID); Device
Lead sponsor: THYROSCOPE INC.; Industry
Eligibility: 22 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Jose, California

Conditions: Bacterial Conjunctivitis
Interventions: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%, Moxifloxacin hydrochloride ophthalmic solution 0.5% as base; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 1 Month and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Epilepsy
Interventions: Lacosamide; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 14
States / cities: Sacramento, California • Washington D.C., District of Columbia • Tampa, Florida + 11 more

Conditions: Glaucoma
Interventions: Brinzolamide 1% ophthalmic solution (Azopt), Placebo eye drops, Latanoprost 0.005% ophthalmic solution (Xalatan); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 35 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Venous Leg Ulcer (VLU)
Interventions: Saline solution, Vashe solution; Device
Lead sponsor: Laboratoires URGO; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastro-esophageal Reflux Disease (GERD)
Interventions: Mucosal Impedance; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atherosclerosis
Interventions: Aliskiren, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 45 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Eyelash Hypotrichosis, Alopecia Areata
Interventions: bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis, Systemic Exertion Intolerance Disease (SEID), Postural Tachycardia Syndrome (POTS), Neurally Mediated Syncope (NMS)
Interventions: Normal Saline, Oral Rehydration Solution; Drug · Dietary Supplement
Lead sponsor: New York Medical College; Other
Eligibility: 15 Years to 29 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Nasal Allergies, Allergies
Interventions: AL-53817 nasal spray solution, Vehicle nasal spray; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Conjunctivitis
Interventions: moxifloxacin, polytrim; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 1 Year to 18 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Bacterial Conjunctivitis
Interventions: AzaSite, Tobramycin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Year and older
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 26
States / cities: Birmingham, Alabama • Littleton, Colorado • Atlantis, Florida + 23 more

Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Interventions: Placebo, PF-06865571, PF-05221304; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 184
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more

Conditions: Cystic Fibrosis
Interventions: AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: BOL-303259-X, Timolol; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Oral Lichen Planus
Interventions: dexamethasone 0.01% solution; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CTX-100 (formerly ETX-100) (hyaluronic acid); Drug
Lead sponsor: Turino, Gerard, M.D.; Individual
Eligibility: 40 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Tucson, Arizona • New York, New York

Conditions: Chronic Back Pain, Chronic Pain (Back / Neck)
Interventions: low intensity focused ultrasound (LIFU); Device
Lead sponsor: Washington D.C. Veterans Affairs Medical Center; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Inhalation Solution, Placebo; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 983 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 12
States / cities: Los Angeles, California • Pismo Beach, California • San Diego, California + 9 more

Conditions: Chronic Allergic Conjunctivitis
Interventions: Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Hair Thinning
Interventions: XVIE; Other
Lead sponsor: Restore Biologics Holdings, Inc. dba Xtressé; Industry
Eligibility: 28 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Maitland, Florida • Marriottsville, Maryland

Search by objective public record fields.

Ultra High Resolution CT to Assess Role of Intramyocardial Fat and Delayed Enhancement in Ventricular Arrhythmogenesis

Exploring Blood Flow Restriction as an Accessible Fitness Solution for Healthy Aging in Seniors

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE)

AL-15469A for the Treatment of Bacterial Conjunctivitis

A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

EVALUATION OF THE EFFICACY AND TOLERANCE OF VASHE SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF VENOUS OR MIXED LEG ULCERS PRESENTING INFLAMMATORY SIGNS SUGGESTING HEAVY BACTERIAL LOAD

HRIM vs Mucosal Impedance in GERD Participants

Aliskiren Effect on Aortic Plaque Progression

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients

Safety and Efficacy of AL-53817 Nasal Spray Solution

Moxifloxacin vs. Polytrim for Conjunctivitis

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Dexamethasone to Treat Oral Lichen Planus

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

Low Intensity Focused Ultrasound for Chronic Pain: High Resolution Targeting of The Human Insula

Tiotropium / Respimat One-Year Study

Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model

Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair